Looking for dividend stocks yielding 3% or more might seem pretty specific. Remember, though, the logic behind investing in underrated stocks is straightforward: Buy low and sell high in order to s...

Currently, the S&P 500 and many sectors are outperforming the healthcare sector, presenting an opportunity to explore assets within this sector during the current period of apathy towards it. Astra...

Abbott Laboratories and AbbVie used to be one and the same company. Both have raised their payouts for 51 years in a row, making them Dividend Kings.

The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have bro...

Top-shelf dividend stocks tend to trade at hefty premiums. Amgen and Bristol Myers Squibb are two clear exceptions to this general rule of thumb.

The market's fear indicator, the VIX index, is bobbing along at long-term lows and gives little indication of a looming correction, but investors should assume one is brewing. The index is down at ...

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF, with a few minor twists. The portfolio fell by 0.57% in August, o...

In the grand tapestry of the investment world, one thread that continues to shine is biotech stocks to buy and hold. It's no secret that delving into biotech investments can be incredibly challengi...

AbbVie has shown resilience and strength despite the patent loss of its best-selling drug, Humira. The company has reported impressive earnings, robust sales in various segments, and a promising pi...

AbbVie's future growth depends on improving its balance of drugs offered, in contrast to its Humira-dependent first decade. Skyrizi and Rinvoq should offset the decline in Humira sales, but further...

Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards of minority v...

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of ...

Med tech has been on the skids for no fault of its own. It's not the industry's fault that price action was driven to a frothy bubble by COVID-inspired trading outlooks or that the market has norma...

Financial opportunities are as abundant as they are volatile. Seizing a selected group of blue-chip stocks to buy could lead to unparalleled investor growth.

The article ranks 5 dividend growth stocks based on their quality, focusing on factors such as balance sheet, management, growth, and stability. The Home Depot is ranked as a "MUST OWN" stock due t...